Active Anti-VEGF Ab Therapy to Control Neoangiogenesis in Malignant Tumors

摘要

Neoangiogenesis, characteristic feature of malignant tumor microenvironment, is dependent on the VEGF released by cancer cells. Passive administration of mAbs to VEGF (Bevacizumab), performed by Genentech, improved the medical status of patients under chemotherapy. We proposed to block the VEGF-induced neoangiogenesis with high titers of neutralizing polyclonal anti-VEGF Abs, induced by an active anti-VEGF immunization using a non toxic but immunogenic muVEGF derivative, i.e. muVEGF kinoid. Immunization of mice with this kinoid proved to be fully innocuous and elicited a strong humoral but no cellular response to the cytokine.